TKT and chronic myelogenous leukemia, BCR-ABL1 positive: Ponatinib recently received FDA approval for the treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia and chronic myeloid leukaemia resistant to other TK inhibitors.